ArticlePloS one2026
Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little information is available regarding the factors that contribute to the occurrence of right innominate vein stenosis in patients with chemoports. Thus, the aims of this study were to evaluate the prevalence of chemoport-related right innominate vein stenosis (CR-RIVS) in patients with colorectal cancer and to identify factors associated with increased CR-RIVS risk. This retrospective study included patients with colorectal cancer (age, ≥ 19 years) who underwent their first chemoport insertion via the right internal jugular vein between August 2015 and August 2020. The prevalence of CR-RIVS was evaluated using follow-up contrast-enhanced chest computed tomography post-chemoport insertion. Risk factors were analyzed using Classification and Regression Tree, Kaplan-Meier survival, and Cox regression analyses. A subgroup analysis was also conducted among patients in palliative care to assess the impact of bevacizumab and cetuximab treatment on the prevalence of CR-RIVS. Among 1,442 patients with colorectal cancer (mean age, 62.1 ± 11.8 years; 850 males), the prevalence of CR-RIVS was 6.6%. The median time from chemoport insertion to CR-RIVS occurrence was 405 days (interquartile range, 256-908 days). The Classification and Regression Tree analysis identified palliative settings as the key predictor of CR-RIVS. Age, palliative settings, and a time×palliative setting interaction were identified as statistically significant variables (p < 0.001). In the 728 palliative patients, bevacizumab treatment was significantly associated with a higher risk of CR-RIVS (hazard ratio = 1.51, 95% confidence interval: 1.25-1.82, P < 0.001), whereas cetuximab was not (p = 0.85). The CR-RIVS-free probability was lower in patients receiving palliative chemotherapy than in those undergoing adjuvant chemotherapy (p < 0.001); it was also lower in the bevacizumab-treated patients (p < 0.001) in the palliative setting subgroup analysis. In summary, the prevalence of CR-RIVS was 6.6% in patients with colorectal cancer. Bevacizumab use showed the strongest association with CR-RIVS occurrence in the palliative subgroup analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.